BACKGROUND: Previous research demonstrated the efficacy of sustained release bupropion (bupropion SR) for smoking cessation in whites as well as moderate to heavy (≥10 cigarettes per day [CPD]) African American smokers. We evaluated whether bupropion SR was effective for smoking cessation among African American light smokers (≤10 CPD). METHODS: A randomized, double-blind placebo-controlled trial was conducted from December 27, 2007, to May 13, 2010. All participants were African American light smokers (≤10 CPD), aged 18 years or older. Participants were randomly assigned to receive 300 mg bupropion SR (150 mg once daily for 3 days and then 150 mg twice daily) (n = 270 participants) orplacebo (n = 270 participants) for 7 weeks, and up to six sessions of health education counseling. Serum cotinine was measured at baseline (week 0). The primary outcome was salivary cotinine-verified 7-day point prevalence smoking abstinence at week 26; a cut point of 15 ng/mL differentiated smokers from nonsmokers. Salivary cotinine-verified smoking abstinence at end of medication treatment at week 7 was also examined. Odds ratios (OR) for smoking abstinence and 95% confidence intervals (CIs) were calculated using logistic regression models. All statistical tests were two-sided. RESULTS:Participants at baseline visit (week 0) smoked an average of 8.0 CPD and had a mean serum cotinine level of 275.8 ng/mL (SD = 155.8 ng/mL); most used menthol cigarettes (83.7%) and smoked within 30 minutes of waking (72.2%). After imputing those lost to follow-up as smokers, no statistically significant difference in long-term smoking abstinence rates at week 26 was observed between bupropion SR and placebo groups (13.3% vs 10.0%, OR = 1.39, 95% CI = 0.82 to 2.35, P = .23). Cotinine-verified smoking abstinence rate at end of medication week 7 was higher in the bupropion SR vs placebo group (23.7% vs 9.6%, OR = 2.92, 95% CI = 1.78 to 4.77, P < .001). CONCLUSIONS:Bupropion SR was effective in promoting smoking cessation during the medication phase of treatment but showed no effect on long-term smoking cessation among African American light smokers. More research is needed to identify strategies for sustaining abstinence among African American light smokers.
RCT Entities:
BACKGROUND: Previous research demonstrated the efficacy of sustained release bupropion (bupropion SR) for smoking cessation in whites as well as moderate to heavy (≥10 cigarettes per day [CPD]) African American smokers. We evaluated whether bupropion SR was effective for smoking cessation among African American light smokers (≤10 CPD). METHODS: A randomized, double-blind placebo-controlled trial was conducted from December 27, 2007, to May 13, 2010. All participants were African American light smokers (≤10 CPD), aged 18 years or older. Participants were randomly assigned to receive 300 mg bupropion SR (150 mg once daily for 3 days and then 150 mg twice daily) (n = 270 participants) or placebo (n = 270 participants) for 7 weeks, and up to six sessions of health education counseling. Serum cotinine was measured at baseline (week 0). The primary outcome was salivary cotinine-verified 7-day point prevalence smoking abstinence at week 26; a cut point of 15 ng/mL differentiated smokers from nonsmokers. Salivary cotinine-verified smoking abstinence at end of medication treatment at week 7 was also examined. Odds ratios (OR) for smoking abstinence and 95% confidence intervals (CIs) were calculated using logistic regression models. All statistical tests were two-sided. RESULTS:Participants at baseline visit (week 0) smoked an average of 8.0 CPD and had a mean serum cotinine level of 275.8 ng/mL (SD = 155.8 ng/mL); most used menthol cigarettes (83.7%) and smoked within 30 minutes of waking (72.2%). After imputing those lost to follow-up as smokers, no statistically significant difference in long-term smoking abstinence rates at week 26 was observed between bupropion SR and placebo groups (13.3% vs 10.0%, OR = 1.39, 95% CI = 0.82 to 2.35, P = .23). Cotinine-verified smoking abstinence rate at end of medication week 7 was higher in the bupropion SR vs placebo group (23.7% vs 9.6%, OR = 2.92, 95% CI = 1.78 to 4.77, P < .001). CONCLUSIONS:Bupropion SR was effective in promoting smoking cessation during the medication phase of treatment but showed no effect on long-term smoking cessation among African American light smokers. More research is needed to identify strategies for sustaining abstinence among African American light smokers.
Authors: Jasjit S Ahluwalia; Kolawole Okuyemi; Nicole Nollen; Won S Choi; Harsohena Kaur; Kim Pulvers; Matthew S Mayo Journal: Addiction Date: 2006-06 Impact factor: 6.526
Authors: Ivana T Croghan; Richard D Hurt; Shaker R Dakhil; Gary A Croghan; Jeff A Sloan; Paul J Novotny; Kendrith M Rowland; Albert Bernath; Mary L Loots; Nguyet A Le-Lindqwister; Loren K Tschetter; Stewart C Garneau; Kathleen A Flynn; Larry P Ebbert; Donald B Wender; Charles L Loprinzi Journal: Mayo Clin Proc Date: 2007-02 Impact factor: 7.616
Authors: Kolawole S Okuyemi; Lisa Sanderson Cox; Nicole L Nollen; Tricia M Snow; Harsohena Kaur; Won Choi; Niaman Nazir; Matthew S Mayo; Jasjit S Ahluwalia Journal: Am J Health Promot Date: 2007 Jan-Feb
Authors: Steven S Fu; Molly M Kodl; Anne M Joseph; Dorothy K Hatsukami; Eric O Johnson; Naomi Breslau; Baolin Wu; Laura Bierut Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-06-26 Impact factor: 4.254
Authors: Timothy B Baker; Megan E Piper; Danielle E McCarthy; Daniel M Bolt; Stevens S Smith; Su-Young Kim; Suzanne Colby; David Conti; Gary A Giovino; Dorothy Hatsukami; Andrew Hyland; Suchitra Krishnan-Sarin; Raymond Niaura; Kenneth A Perkins; Benjamin A Toll Journal: Nicotine Tob Res Date: 2007-11 Impact factor: 4.244
Authors: Lisa Sanderson Cox; Carrie A Bronars; Janet L Thomas; Kolawole S Okuyemi; Gary King; Matthew S Mayo; Jasjit S Ahluwalia Journal: Nicotine Tob Res Date: 2007-06 Impact factor: 4.244
Authors: Robert West; Christine L Baker; Joseph C Cappelleri; Andrew G Bushmakin Journal: Psychopharmacology (Berl) Date: 2007-12-15 Impact factor: 4.530
Authors: Taneisha S Buchanan; Carla J Berg; Lisa Sanderson Cox; Niaman Nazir; Neal L Benowitz; Lisa Yu; Olivia Yturralde; Peyton Jacob; Won S Choi; Jasjit S Ahluwalia; Nicole L Nollen Journal: Nicotine Tob Res Date: 2012-02-24 Impact factor: 4.244
Authors: Nicole L Nollen; Jasjit S Ahluwalia; Yang Lei; Qing Yu; Taneisha S Scheuermann; Matthew S Mayo Journal: Nicotine Tob Res Date: 2015-05-20 Impact factor: 4.244
Authors: Kim Pulvers; Taneisha S Scheuermann; Ashley S Emami; Brittany Basora; Xianghua Luo; Samir S Khariwala; Jasjit S Ahluwalia Journal: Nicotine Tob Res Date: 2014-07-10 Impact factor: 4.244
Authors: Meghan J Chenoweth; Andy Z X Zhu; Lisa Sanderson Cox; Jasjit S Ahluwalia; Neal L Benowitz; Rachel F Tyndale Journal: Pharmacogenet Genomics Date: 2014-03 Impact factor: 2.089
Authors: Julie-Anne Tanner; Andy Z Zhu; Katrina G Claw; Bhagwat Prasad; Viktoriya Korchina; Jianhong Hu; HarshaVardhan Doddapaneni; Donna M Muzny; Erin G Schuetz; Caryn Lerman; Kenneth E Thummel; Steven E Scherer; Rachel F Tyndale Journal: Pharmacogenet Genomics Date: 2018-01 Impact factor: 2.089
Authors: Neal L Benowitz; Gideon St Helen; Natalie Nardone; Lisa Sanderson Cox; Peyton Jacob Journal: Nicotine Tob Res Date: 2020-02-06 Impact factor: 4.244
Authors: Andy Z X Zhu; Qian Zhou; Lisa Sanderson Cox; Jasjit S Ahluwalia; Neal L Benowitz; Rachel F Tyndale Journal: Drug Metab Dispos Date: 2014-09-03 Impact factor: 3.922
Authors: Babalola Faseru; Nicole L Nollen; Matthew S Mayo; Ron Krebill; Won S Choi; Neal L Benowitz; Rachel F Tyndale; Kolawole S Okuyemi; Jasjit S Ahluwalia; Lisa Sanderson Cox Journal: Addict Behav Date: 2012-11-29 Impact factor: 3.913